





OFFICE OF THE MANAGING DIRECTOR ASSAM MEDICAL SERVICES CORPORATION LIMITED

Central Drug Ware House Campus, Patherquery, Narengi, Guwahati, Assam-781026 Email id: md-amscl@assam.gov.in

e-File No.: 505641/20127

From: Managing Director,

Assam Medical Services Corporation Limited

To: Unicure India Ltd

Unit 1, C-21, 22, 23, Sector-3, Noida

Sub: Firm Debarment Notice for non completion of required supply (minimum 90% supply) of **22 nos. of essential drugs against 25 nos. of POs**

Ref:

1.Tender No.: NHM-43018/2022-PROC/AMSCL/ECF: 255581/150953, Dated. 09/02/2023) & all relevant corrigendum notices issued against this tender.

- 2. Purchase order issued from AMSCL with vide P.O No. placed at Annexure-A.
- 3. Show-cause notice issued vide letter no. 505641/12163, dated: 17-03-2025
- 4. Notice cum Extension issued vide letter no. 505641/12644, dated: 23-03-2025.
- 5. Show-cause notice issued vide letter no. 505641/14733 & . 505641/14764 dated : 21-05-2025
- 6. Notice cum Extension issued vide letter no. 505641/15686, dated: 21-06-2025.
- 7. Show-cause notice issued vide letter no. 505641/15943, dated: 30-06-2025.
- 8. Notice cum Extension issued vide letter no. 505641/17283, dated : 31-07-2025 & 505641/18659, dated : 13-09-2025.
- 9. Show-cause notice issued vide letter no. 505641/18686, dated: 13-09-2025.
- 10. Notice cum Extension issued vide letter no. 505641/19078, dated : 08-10-2025 & 505641/18903, dated : 10-10-2025.
- 11. Final Notice cum Extension issued vide letter no. 505641/19668, dated : 04-11-2025.

Sir/Madam,

With reference to the subject cited above, I am to inform you that your company was awarded with the Purchase Orders vide POs (as detailed at **Annexure-A**) to this letter, against your agreement with AMSCL vide tender under reference at Pt.1 above.

But your company not yet complete the required supply of essential drugs within the contractual delivery period (75 days from placing of PO), period with highest late delivery charges has also crossed, (i.e., @2% of the value of delayed goods per week of delay or part thereof subject to a maximum of 10% of the total order value).

AMSCL Authority found that said items are essential in nature for needy patients getting treatment in Govt. Hospitals of the state, therefore show cause notice was

served to your company vide letter under reference at pt.3, pt.5, pt. 7 & pt.9 (above) and delivery extension with additional time period (under reference at pt.4, pt.6, pt.8, pt.10, pt.11 was given. (Details on non-completion of supply report as per DVDMS portal is attached with this letter at Annexure-A

All efforts as mentioned above via several notices, show-causes, extensions, official communications via mail & telephonic calls were made to get the supply from your company and enough opportunities were given to your company to execute supplies of essential drug but your company was found defaulter in terms of completion of supplies in a time bound manner causing non availability & hindrance in public service and also resulted in increase in out-of-pocket expenditure of the patients.

The following communications were sent to your company, providing ample opportunity for compliance:

- 1. **17.03.2025** Show-cause notice (Letter No. 505641/12163)
- 2. **23.03.2025** Notice-cum-Extension (Letter No. 505641/12644)
- 3. **21.05.2025** Show-cause notice (Letter Nos. 505641/14733 & 505641/14764)
- 4. **21.06.2025** Notice-cum-Extension (Letter No. 505641/15686)
- 5. **30.06.2025** Show-cause notice (Letter No. 505641/15943)
- 6. **31.07.2025** Notice-cum-Extension (Letter No. 505641/17283)
- 7. **13.09.2025** Notice-cum-Extension (Letter No. 505641/18659)
- 8. **13.09.2025** Show-cause notice (Letter No. 505641/18686)
- 9. **08.10.2025** Notice-cum-Extension (Letter No. 505641/19078)
- 10. **10.10.2025** Notice-cum-Extension (Letter No. 505641/18903)
- 11. **04.11.2025** Final Notice-cum-Extension (Letter No. 505641/19668)

Further extension has no valid ground to be considered as already in the Final Notice cum Extension letter, it was clearly mentioned as the last communication and upon non-completion of desired supplies product/ firm debarment will be proceed. But as per DVDMS portal details as on date, a total non supply of 22 nos. of essential drugs against 25 nos. of POs, where 15 POs were found below 80% supply, 10 POs are found above 80% but below 90% supply and for 3 POs supply has not been started and the tender norms require a minimum of 90% of the supply obligation to be fulfilled; for non-incorporation of administrative penalty.

Therefore, in the greater public & patient interest, your company 'Unicure India Ltd" is hereby blacklisted and debarred from participating in any tender for 3 (three) years (from the date of issuing this letter) as per referred tender Clause No.5, Sub Clause-H, Pt.no.(ii), Pt.no. (iii) & Sub Clause-M for non completion of required supply (minimum 90% supply) of 22 nos. of essential drugs against 25 nos. of POs, (details are placed at Annexure-A).

The relevant administrative and financial penalty clauses of the tender under

reference are detailed as below-

Clause No.5, "Terms & Conditions" Sub Clause-H, "Debarment/Blacklisting for failure in execution of supply/non supply/default in supply".

Pt. no.(ii) Firm Debarment: The firm shall be blacklisted and debarred from participating in any tender by the TIA or procuring agency for 3 (three) years if the company is debarred for all the items (where it has RC-"Rate Contract" for less than 3 items) or at least 3 items (where it holds RC-"Rate Contract" for more than equal to 3 items),

Pt. no. (iii) Forfeiture of Performance Security: b) In case of Firm debarment: In addition to firm debarment the entire performance security deposited by the supplier shall be forfeited and apportioned towards financial penalty.

Clause No.5, Sub Clause-M. Alternative Purchase:

i. If the empanelled supplier fails to execute the supply within the stipulated time, AMSCL is at liberty to make alternative purchase of the items for which the Purchase Orders have been placed from any other sources (such as Public Sector undertakings at their rates, empanelled bidders, and bidders who have been technically qualified in the said bid) or in the open market even at higher rates at the risk and the cost of the supplier and in such cases AMSCL shall have every right to recover the cost and impose penalty, apart from termination of the contract for the default. ii. In the event of making ALTERNATIVE PURCAHSE, the supplier will be imposed penalty apart from forfeiture of Security Deposit. The excess expenditure over and above contracted prices incurred by AMSCL in making such purchases from any other source or from the open market shall be recovered from the Security Deposit or from any other money due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier or from his properties, as per rules.

Encl: Annexure-A (non-completion details of ordered drugs as per DVDMS portal as on date : 14.11.2025

This is for favour of your kind information.

Managing Director,
Assam Medical Services Corporation Limited

Memo e File No.: 505641/20128-20137

Copy to the:

- 1. Commissioner & Secretary to the Govt. of Assam, H & FW Department & Chairman AMSCL for kind information
- 2. Commissioner & Secretary to the Govt. of Assam, MERD for kind information
- 3. Mission Director, NHM, Assam for kind information
- 4. Director of Medical Education, Assam for kind information.
- 5. Director of Health Services for kind information.
- 6. Executive Director, NHM, Assam for kind information.
- 7. Principal cum Chief Superintendent/Superintendent, all Medical Colleges for kind information.
- 8. Jt. DHS, all Districts for kind information.

- 9. DDSM-all Districts and M.O i/c & Pharmacist-all Medical Colleges and Admin Manager & Pharmacist & AMSCL State Store for information.
- 10. P.S to the Hon'ble Minister, H & FW for kind information to the Hon'ble Minister.

-e-signed Managing Director, Assam Medical Services Corporation Limited

Annexure-A

DRUG AND VACCINE DISTRIBUTION MANAGEMENT SYSTEM **NHM and AMSCL** Guwahati **PO Delivery Status** As on Date :- 14-Nov-25 Scheduled % of Supplier Delivery Ordered Approval passed PO No Item Name date of Date Qty (A) delivery since No Name Davs delivery approval Unicure 18-10-2020102385689 31-12-2024 4581130 87.35 Metronidazole Tablet 400 mg India Ltd 2024 75 392 19-11-Unicure India Ltd 2020102386627 Chlorpromazine Tablet 50 mg 2024 75 01-02-2025 5700 0 360 Unicure 19-11-India Ltd 2020102386645 75 01-02-2025 5050 86.14 360 Valganciclovir Tablet 450 mg 2024 11-12-Unicure Acyclovir Tablet 200 mg 2020102387002 23-02-2025 107700 India Ltd 2024 75 338 11-12-Unicure Letrozole Tablet 2.5 mg India Ltd 2020102387018 2024 75 23-02-2025 62700 79.9 338 Levodopa (A) Plus Carbidopa (B) Unicure 11-12-Tablet 100 mg (A) Plus 10 mg (B) 23-02-2025 22340 70.9 India Ltd 2020102387019 2024 75 338 01-03-Unicure India Ltd 2020102387245 14-05-2025 712700 Doxylamine Succinate Tablet 10 mg 2025 75 81.75 Unicure 01-03-205900 8 Escitalopram Tablet 10 mg India Ltd 2020102387246 2025 75 14-05-2025 80.57 258 Unicure 01-03-India Ltd 2020102387271 175100 Levetiracetam Tablet 250 mg 75 14-05-2025 82.07 258 2025 01-03-Unicure 14-05-2025 264800 Phenytoin Tablet 100 mg tablet India Ltd 2020102387295 2025 75 258 Unicure 01-03-11 Thiamine Tablet 100 mg India Ltd 2020102387318 2025 75 14-05-2025 107100 84.97 258 Acetylsalicylic Acid Enteric coated Unicure 01-03-India Ltd 2020102387324 505500 2025 75 14-05-2025 86.63 258 Tablet 75 mg Ascorbic acid (Vitamin C) Tablet 500 01-03-Unicure India Ltd 2020102387373 14-05-2025 945200 80.95 75 258 13 2025 Cefixime Oral Suspension 100 mg/5 Unicure 01-03-India Ltd 2020102387429 14-05-2025 14 ml 61400 50.49 2025 75 258 01-03-Unicure 75 14-05-2025 857400 38.84 258 Cefuroxime Tablet 500 mg India Ltd 2020102387451 2025 01-03-Unicure 4266200 16 Metformin Tablet SR 500 mg India Ltd 2020102387516 14-05-2025 81.85 258 2025 75 Unicure 01-03-44700 17 Thiamine Tablet 100 mg India Ltd 2020102387612 2025 75 14-05-2025 47.65 258 Sodium valproate Oral Solution 200 Unicure 01-03-75 14-05-2025 3850 mg/5ml India Ltd 2020102387657 2025 22.08 258 Metronidazole Oral suspension 200 01-03-Unicure India Ltd 2020102387864 14-05-2025 40500 52.59 mg/5 ml 75 258 2025 01-03-20 Linezolid Tablet 600 mg 106600 India Ltd 2020102387913 2025 14-05-2025 258

27	258
	236
0	258
27.31	226
0	157
24	157
	27.31